Adaptive Biotechnologies (ADPT) vs CareDx (CDNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CareDx (CDNA) has outperformed Adaptive Biotechnologies (ADPT) over the past year, gaining 329.7% versus a gain of 83.1%. Over five years, CDNA leads with a -11.2% price change compared with -21.6% for ADPT. Adaptive Biotechnologies is the larger company by market cap ($4.19 billion vs $3.26 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | CDNA |
|---|---|---|
| Share price | $26.28 | $63.04 |
| Market cap | $4.19B | $3.26B |
| 1-day change | -2.30% | -1.18% |
| YTD return | +61.82% | +234.61% |
| 1-year return | +83.14% | +329.72% |
| 5-year return | -21.55% | -11.21% |
| P/E ratio (TTM) | — | 30.60 |
| Forward P/E | — | 48.87 |
| EPS (TTM) | $-0.40 | $2.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | — |
| Revenue growth (YoY) | +54.77% | — |
| Net income (latest FY) | $-59.50M | — |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | — |
| Net margin | -21.48% | — |
| 52-week high | $30.74 | $72.51 |
| 52-week low | $12.00 | $13.95 |
| Distance from 52-week high | -14.51% | -13.06% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +7.72% | -6.68% |
| Average volume | 2.39M | 1.28M |
| Shares outstanding | 159.60M | 51.73M |
| Employees | 624 | 761 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CDNA has outperformed ADPT by 246.6 percentage points over the past year.
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About CareDx
CDNA stock →CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Health Care · Medical Specialities · 761 employees
ADPT vs CDNA FAQ
Which is bigger, Adaptive Biotechnologies or CareDx?
Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.19B compared with $3.26B for CareDx (CDNA).
Which stock has performed better over the past year, ADPT or CDNA?
CDNA returned +329.72% over the past 12 months, compared with +83.14% for ADPT (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and CareDx in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Adaptive Biotechnologies and Medical Specialities for CareDx.